BBWA
RYTM icon

Bell & Brown Wealth Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Bell & Brown Wealth Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-41,600
Closed -$1.21M – 71
2022
Q4 		$1.21M Buy
+41,600
New +$1.07M 0.67% 48
2022
Q3 		– Sell
-70,400
Closed -$293K – 71
2022
Q2 		$293K Sell
70,400
-47,000
-40% -$257K 0.16% 66
2022
Q1 		$1.35M Buy
+117,400
New +$1.03M 0.61% 51

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Bell & Brown Wealth Advisors's RYTM Position: Q1 2023 in Review

Bell & Brown Wealth Advisors sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2023, closing a stake of 41,600 shares — an estimated $1.21M sold.

Bell & Brown Wealth Advisors first reported a position in RYTM in Q1 2022 and held it in 3 quarters. The position peaked at $1.35M in Q1 2022. 126 funds tracked by Wall St. Rank hold RYTM as of Q1 2023.

  • Bell & Brown Wealth Advisors reported no remaining Rhythm Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Bell & Brown Wealth Advisors sold 41,600 Rhythm Pharmaceuticals shares in Q1 2023, an estimated $1.21M.
  • Bell & Brown Wealth Advisors first reported a position in Rhythm Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Bell & Brown Wealth Advisors's Rhythm Pharmaceuticals position peaked at $1.35M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2023.

Based on Bell & Brown Wealth Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.